Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $17.75 Consensus PT from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $17.75.

A number of equities analysts have recently commented on ATRA shares. Canaccord Genuity Group reissued a “buy” rating and issued a $17.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th.

Institutional Trading of Atara Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in ATRA. Geode Capital Management LLC lifted its stake in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares during the last quarter. Staley Capital Advisers Inc. increased its stake in Atara Biotherapeutics by 25.0% in the 4th quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company’s stock worth $666,000 after purchasing an additional 10,000 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics in the fourth quarter valued at approximately $169,000. Marshall Wace LLP purchased a new stake in shares of Atara Biotherapeutics during the fourth quarter valued at approximately $332,000. Finally, Birchview Capital LP bought a new position in shares of Atara Biotherapeutics in the fourth quarter worth approximately $293,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Stock Down 10.1%

Atara Biotherapeutics stock opened at $6.84 on Monday. The stock has a market cap of $40.77 million, a price-to-earnings ratio of -0.27 and a beta of 0.30. The business has a 50-day simple moving average of $6.66 and a 200 day simple moving average of $9.17. Atara Biotherapeutics has a 52 week low of $5.01 and a 52 week high of $18.71.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 earnings per share for the quarter, topping the consensus estimate of ($3.07) by $6.57. The company had revenue of $98.10 million during the quarter, compared to the consensus estimate of $4.30 million. On average, research analysts anticipate that Atara Biotherapeutics will post -10.39 earnings per share for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.